CompuGroup Medical SE & Co. KGaA / DE000A288904
15.07.2024 - 07:28:10CompuGroup Medical SE & Co. KGaA publishes half-year figures for the financial year 2024
| CompuGroup Medical SE & Co. KGaA / Key word(s): Half Year Results CompuGroup Medical SE & Co. KGaA publishes half-year figures for the financial year 2024 15.07.2024 / 07:28 CET/CEST The issuer is solely responsible for the content of this announcement. CompuGroup Medical SE & Co. KGaA publishes half-year figures for the financial year 2024 Against the backdrop of the ad-hoc announcement on July 9, 2024, the general partner of CompuGroup Medical SE & Co. KGaA (ISIN: DE000A288904 | WKN: A28890) (“CGM”) has decided to prepone the publication of the financial results for the first half of the financial year 2024. The financial results for the first half of the financial year are as follows: Group revenues decreased by 6% year-on-year to EUR 562 million (prior year period: EUR 595 million), mainly due to TI one-time effects in the prior year Organic revenues decreased by 5% year-on-year (prior year period +12%), adjusted for prior-year TI one-time effects +1% year-on-year Recurring revenues grew by 6% year-on-year to EUR 423 million (prior year period EUR 401 million) Recurring revenue share at 75% (prior year period 67%) Adjusted EBITDA declined by 14% year-on-year to EUR 114 million (prior year period: EUR 133 million) Adjusted earnings per share (EPS) are down to EUR 0.81 (prior year period: EUR 1.07) Free cash flow amounted to EUR 39 million (prior year period: EUR 83 million) Net debt increased from EUR 703 million by the end of 2023 to EUR 779 million by the end of June 2024 Leverage has increased from 2.8x by the end of 2023 to 3.3x by the end of June 2024 In the Ambulatory Information Systems (AIS) segment (since 2024 including the former CHS segment) revenues in the first six months of 2024 decreased by 10% year-on-year to EUR 338 million, mainly due to one-time effects related to the Telematics Infrastructure hardware connector exchange and software upgrade in the first half of the prior year. Organically and excluding the TI one-time effects, revenues were on the prior year level. Recurring revenues grew by 4%, increasing the recurring share by 10 percentage points to 77%. Revenues in the Hospital Information Systems (HIS) segment increased in the first six months of 2024 by 4% to EUR 156 million. Adjusted for acquisitions and FX effects, organic growth was 4%, mainly attributable to increased revenues in Austria, Spain and from projects related to the Hospital Future Act. Recurring revenues increased to EUR 113 million, corresponding to 73% of total revenues. In the Pharmacy Information Systems (PCS) segment revenues declined in the first six months of 2024 by 1 % to EUR 68 million, in particular due to strong non-recurring sales in prior year period. Organically, revenues declined by 1%. Recurring revenues in the PCS segment increased by 6% to EUR 49 million compared to the same period of the prior year. In all three segments investments into the future of e-health were made including Artificial Intelligence, data-based and patient-centered solutions. R&D expenses for the group amounted to EUR 125 million in the first six months of 2024 (prior year period: EUR 120 million). On July 9, CGM revised its guidance for the financial year 2024 for organic revenue growth and adjusted EBITDA. The half-year interim report published today contains the full revised guidance for the financial year 2024. The revised guidance is as follows (compared to the original guidance published on February 7, 2024): Group Organic revenue development (adjusted for acquisitions and currency effects) is now expected in a range between -2% and 0% year-on-year (previously 4 % and 6 %). The share of recurring revenues as of total revenues is expected unchanged between 65 % and 70 %. Adjusted EBITDA is now expected in a range between EUR 220 million and EUR 250 million (previously EUR 270 million and EUR 310 million). Adjusted earnings per share (diluted) are now expected in a range between EUR 1.55% and EUR 1.95% (previously: increase of approximately 10 % compared to the prior year). Free cash flow is now expected in a range between EUR 40 million and EUR 60 million (previously EUR 70 million and EUR 100 million). Segments For the AIS segment CGM now expects an organic revenue decrease by a low to mid single-digit percentage rate (previously growth in the low to mid-single digit percentage range). For the HIS segment CGM now expects an organic revenue growth by a low to mid single-digit percentage rate (previously growth in the mid to high-single digit percentage range). For the PCS segment CGM continues to expect an unchanged organic revenue growth in the low to mid single-digit percentage range. The full financial statements for the first half including explanations of the adjustments in earnings figures year can be found in the half year financial report at www.cgm.com/ir-publications. 15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1945727 |
| End of News | EQS News Service |
| |
